Get started
DEXCOM INCDEXCOM INCDEXCOM INC

DEXCOM INC

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

DC4 chart


Full chart

Key facts today

DexCom, Inc. (DXCM) has settled patent disputes with Abbott Laboratories regarding glucose monitoring products, resulting in dismissed cases and a 10-year agreement to prevent future legal conflicts.
Analyze the impactAnalyze the impact

DC4 upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪27.98 B‬ CHF
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
39.619
Basic EPS (TTM)
1.477 CHF
Net income (FY)
‪455.91 M‬ CHF
Revenue (FY)
‪3.05 B‬ CHF
Shares float
‪385.65 M‬
Beta (1Y)
0.38

Employees


Employees (FY)
‪9.6 K‬
Change (1Y)
‪+2 K‬ +26.32%
Revenue / Employee (1Y)
‪317.68 K‬ CHF
Net income / Employee (1Y)
‪47.49 K‬ CHF

About DexCom, Inc.


Sector
Health Technology
Industry
Medical Specialties
CEO
Kevin Ronald Sayer
Website
dexcom.com
Headquarters
San Diego
Founded
1999
FIGI
BBG00LVD7CL3
DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

DC4 news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

DC4 highest yielding bonds


DXCM5195221
DexCom, Inc. 0.25% 15-NOV-2025
Yield to maturity
4.39%
Maturity date
Nov 15, 2025
DXCM5813816
DexCom, Inc. 0.375% 15-MAY-2028
Yield to maturity
3.86%
Maturity date
May 15, 2028

Explore more bonds 

Frequently Asked Questions


The current price of DC4 is 71.701 CHF — it has increased by 20.45% in the past 24 hours. Watch DEXCOM INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange DEXCOM INC stocks are traded under the ticker DC4.
DC4 stock has risen by 20.45% compared to the previous week, the month change is a 20.45% rise, over the last year DEXCOM INC has showed a −15.97% decrease.
We've gathered analysts' opinions on DEXCOM INC future price: according to them, DC4 price has a max estimate of 111.63 CHF and a min estimate of 66.98 CHF. Watch DC4 chart and read a more detailed DEXCOM INC stock forecast: see what analysts think of DEXCOM INC and suggest that you do with its stocks.
DC4 reached its all-time high on Nov 1, 2021 with the price of 570.749 CHF, and its all-time low was 56.730 CHF and was reached on Sep 6, 2024. View more price dynamics on DC4 chart.
See other stocks reaching their highest and lowest prices.
DC4 stock is 16.98% volatile and has beta coefficient of 0.38. Track DEXCOM INC stock price on the chart and check out the list of the most volatile stocks — is DEXCOM INC there?
Today DEXCOM INC has the market capitalization of ‪28.23 B‬, it has decreased by −1.17% over the last week.
Yes, you can track DEXCOM INC financials in yearly and quarterly reports right on TradingView.
DEXCOM INC is going to release the next earnings report on Feb 6, 2025. Keep track of upcoming events with our Earnings Calendar.
DC4 earnings for the last quarter are 0.38 CHF per share, whereas the estimation was 0.37 CHF resulting in a 3.56% surprise. The estimated earnings for the next quarter are 0.47 CHF per share. See more details about DEXCOM INC earnings.
DEXCOM INC revenue for the last quarter amounts to ‪842.51 M‬ CHF, despite the estimated figure of ‪839.33 M‬ CHF. In the next quarter, revenue is expected to reach ‪986.60 M‬ CHF.
DC4 net income for the last quarter is ‪114.06 M‬ CHF, while the quarter before that showed ‪129.01 M‬ CHF of net income which accounts for −11.59% change. Track more DEXCOM INC financial stats to get the full picture.
No, DC4 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has ‪9.60 K‬ employees. See our rating of the largest employees — is DEXCOM INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. DEXCOM INC EBITDA is ‪712.18 M‬ CHF, and current EBITDA margin is 21.64%. See more stats in DEXCOM INC financial statements.
Like other stocks, DC4 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade DEXCOM INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So DEXCOM INC technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating DEXCOM INC stock shows the neutral signal. See more of DEXCOM INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.